COMMUNIQUÉS West-GlobeNewswire

CONVOCATION À L’ASSEMBLÉE GÉNÉRALE ORDINAIRE 2025 D’IBA SA
12/05/2025
- MERCREDI 11 JUIN 2025 À 10H00 - Cher Actionnaire, Nous avons l’honneur de vous convoquer à l’Assemblée Générale Ordinaire (l’« AGO » ) des actionnaires d’IBA qui se tiendra le mercredi 11 juin 2025 à 10h00 , pour [...]
CONVENING NOTICE TO THE ORDINARY GENERAL MEETING 2025 OF IBA SA
12/05/2025
– WEDNESDAY, JUNE 11, 2025, AT 10:00 A.M. – Dear Shareholder, We have the honor of convening you to the Ordinary General Meeting (the " OGM ") of IBA to be held on Wednesday June 11, 2025 at 10:00 A.M., to deliberate on [...]
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
12/05/2025
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% APG808 demonstrated [...]
Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025
12/05/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025 Männedorf, [...]
Valneva fait un point sur les recommandations d’utilisation d'IXCHIQ® chez les personnes âgées aux États-Unis
12/05/2025
Saint Herblain (France), le 12 mai 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence de santé américaine Food and Drug Administration (FDA [...]
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
12/05/2025
Saint Herblain (France), May, 12 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control [...]
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025
12/05/2025
Press release – No. 8 / 2025 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a [...]
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
12/05/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule [...]
Nanobiotix participera à la 3ème conférence investisseurs annuelle H.C. Wainwright BioConnect au NASDAQ
12/05/2025
PARIS and CAMBRIDGE, Mass., 12 mai 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
12/05/2025
PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to [...]
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
12/05/2025
The REAL8 trial showed that after 52 weeks, once-weekly Sogroya ® (somapacitan) had similar clinical outcomes and safety profile to once-daily Norditropin ® (somatropin) in children born small for gestational age (SGA) [...]
AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2024 et présente un point sur ses activités
12/05/2025
COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS ANNUELS AU 31 DECEMBRE 2024 ET LES EVENEMENTS CLEFS DE LA PERIODE Situation financière et corporate Déficit opérationnel de 6,1 millions d’euros au 31 [...]
AB Science reports its revenues for the year 2024 and provides an update on its activities
12/05/2025
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD Financial and corporate situation Operating deficit of 6,1 million euros as of December 31, 2024, down [...]
RadNet Reports First Quarter Financial Results and Revises Upwards 2025 Financial Guidance Ranges for Revenue and Adjusted EBITDA¹
11/05/2025
First quarter Revenue was negatively impacted by approximately $22 million and Adjusted EBITDA ( 1) was negatively impacted by approximately $15 million as a result of the Southern California wildfires and severe winter [...]
Best Skin Tag Remover 2025: Revitag Review & Top Skin Tag Removal Tips
11/05/2025
Looking for the best skin tag remover in 2025? Discover how Revitag works, plus expert tips on safe, fast, and effective skin tag removal at home. Tallmadge, OH, May 11, 2025 (GLOBE NEWSWIRE) -- Introduction Skin tags— [...]
Akero Therapeutics et HistoIndex présentent de nouvelles analyses de l’essai de phase IIb HARMONY lors de présentations orales et d’affiches lors du congrès 2025 de l’EASL
11/05/2025
L’analyse des résultats de l’EFX au moyen de la pathologie numérique basée sur l’IA souligne le potentiel d’évaluation de la réponse histopathologique Ces données s’ajoutent au nombre croissant de preuves de l’activité [...]
Best Probiotic for Bloating, Gas, and Constipation: Top Probiotic Supplements for Gut Health to Reduce Bloating, Indigestion & Flatulence (YourBiology)
11/05/2025
The best probiotics for bloating and gas include strains like Lactobacillus rhamnosus GG, Lactobacillus acidophilus, and Bifidobacterium lactis, which help balance gut bacteria, improve digestion, and reduce bloating, [...]
Best Vyvanse Alternative Over the Counter for ADHD - Natural Vyvanse Substitute - Noocube
10/05/2025
London, May 10, 2025 (GLOBE NEWSWIRE) -- Vyvanse is a prescription medication that is used to treat ADHD symptoms, but it can be expensive and some people don't like the idea of taking a drug class medicine or stimulant [...]
Akero Therapeutics annonce la publication de l’essai de phase 2b SYMMETRY dans le New England Journal of Medicine
10/05/2025
Les résultats confirment le bénéfice potentiel de l’éfruxifermine (EFX) pour déclencher une amélioration de la fibrose chez les patients atteints de cirrhose compensée (fibrose F4) due à une MASH ; les données à 96 [...]

Pages